MAPS policy advocacy in the second quarter of 2026 centers federal and state psychedelic reform, coalition work, and public education across multiple jurisdictions

MAPS policy advocacy in the second quarter of 2026 focuses on psychedelic law and regulatory reform, coalition building, and public education across federal and state arenas. The update centers institutional efforts to influence policy, support legislative momentum, and expand public understanding of psychedelic issues. Advocacy work likely includes engagement with lawmakers, partner organizations, and grassroots supporters around access, decriminalization, therapeutic frameworks, and implementation questions. The emphasis suggests a mix of strategic campaigning and movement infrastructure rather than a single bill or court case. Quarterly wrap-ups like this matter because psychedelic policy is moving through uneven regional pathways, with reforms shaped by public health concerns, medical access debates, and broader drug policy change. MAPS functions here as a coordinating actor linking policy strategy to mainstream legitimacy and long-term reform.